ARTICLE SUMMARY:
Spiden wants to one day enable preventive medicine with an implant that nondestructively measures biomarkers and drugs within the body in real time. In the near term, the company is creating the building blocks for such a future with products for the noninvasive measurement of biomarkers and drugs in complex biological fluids, be it from patients in the ICU, or media used to produce biologics.
Earlier this year, the announcement of an $18 million funding round for Spiden AG tantalizingly described the start-up as focused on longevity. That might sound elusive, but the company isn’t talking about a mystical journey to the proverbial fountain of youth; it is applying artificial intelligence to biophotonics to analyze blood in vivo.
